Background: Psammoma bodies in cervical smears are rare but may be associated with benign and malignant diseases of the female genital tract. Case: A 52-year-old nulliparous woman presented with a 2-month history of intermittent vaginal spotting and post-coital bleeding. A cervical smear showed an inconclusive high-grade glandular lesion with psammomatous calcification. Previous cervical smears had been normal. This smear contained papillary tissue fragments, occasional spheres of gland-like cells and frequent psammoma bodies. The patient underwent a laparoscopic hysterectomy, bilateral salpingo-oophorectomy and omentectomy. The surface of the omentum and both ovaries contained psammoma bodies with groups of cells identical to those in the cervical smear. Within the omentum, there were invasive malignant epithelioid cells positive for CK7, CK5/6, calretinin, D2-40, WT-1, CK5/6, p16 and EMA. Desmin and PAX-8 immunostains were negative. There was also evidence of BRCA1-associated protein 1 (BAP1) dysfunction compatible with diffuse malignant peritoneal mesothelioma (DMPM). Conclusion: We describe the first reported case of DMPM presenting with an abnormal cervical smear, a rare but important differential diagnosis to consider in abnormal cervical smears showing psammomatous calcification.

Fadare O, Chacho M, Parkash V: Psammoma bodies in cervicovaginal smears: significance and practical implications for diagnostic cytopathology (review). Adv Anat Pathol 2004;11:250-261.
Gould DA, Butler-Manuel SA, et al: Psammoma bodies on routine cervical smear. J R Soc Med 1998;91:383-385.
Nicklin JL, Perrin L, et al: The significance of psammoma bodies on cervical cytology smears. Gynecol Oncol 2001;83:6-9.
Zreik TG, Rutherford TJ: Psammoma bodies in cervicovaginal smears. Obstet Gynecol 2001;97(5 Pt 1):693-695.
Misdraji J, Vaidya A, et al: Psammoma bodies in cervicovaginal cytology specimens: a clinicopathological analysis of 31 cases. Gynecol Oncol 2006;103:238-246.
Parkash V, Chacho MS: Psammoma bodies in cervicovaginal smears: incidence and significance. Diagn Cytopathol 2002;26:81-86.
Kern SB: Prevalence of psammoma bodies in Papanicolaou-stained cervicovaginal smears. Acta Cytol 1991;35:81-88.
Russin VL, Valente PT, Hanjana P: Psammoma bodies in neuroendocrine carcinoma of the uterine cervix. Acta Cytol 1987;31:791-795.
Gattuso P, Reddy VB (eds): Differential Diagnosis in Cytopathology. Cambridge, Cambridge University Press, 2014.
Li S, Boudousquie AC, et al: Aluminum silicate-containing psammoma bodies in a cervicovaginal smear (Pap): cytological, ultrastructural, and radiographic microprobe studies. Diagn Cytopathol 1999;21:122-124.
Alakus H, Yost S, et al: BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma. J Transl Med 2015;13:122.
Bakkum-Gamez J, Dowdy S: Retooling the Pap smear for ovarian and endometrial cancer detection. Clin Chem 2014;60:22-24.
Hjerpe A, Ascoli V, et al: Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Acta Cytol 2015;59:2-16.
Andrici J, Sheen A, et al: Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology. Mod Pathol 2015;28:1360-1368.
Ito T, Hamasaki M, et al: p16/CDKN2A FISH in differentiation of diffuse malignant peritoneal mesothelioma from mesothelial hyperplasia and epithelial ovarian cancer. Am J Clin Pathol 2015;143:830-838.
Murali R, Wiesner T, Scolyer RA: Tumours associated with BAP1 mutations. Pathology 2013;45:116-126.
Farzin M, Toon CW, et al: Loss of expression of BAP1 predicts longer survival in mesothelioma. Pathology 2015;47:302-327.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.